Nucleic acid binding, mitochondrial RNA binding complex 1 subunit Uncharacterized
Source | Evidence on protein | Close homologs |
---|---|---|
Cuervo et al. | no | yes: 0 |
Hassani et al. | no | yes: 0 |
Forrest at al. (metacyclic) | no | yes: 0 |
Forrest at al. (procyclic) | no | yes: 0 |
Silverman et al. | no | yes: 0 |
Pissara et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Pires et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Silverman et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Jamdhade et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
DeepLoc | ||
SignalP6 | no | yes: 0, no: 6 |
NetGPI | no | yes: 0, no: 6 |
Term | Name | Level | Count |
---|---|---|---|
GO:0005737 | cytoplasm | 2 | 1 |
GO:0031974 | membrane-enclosed lumen | 2 | 1 |
GO:0031981 | nuclear lumen | 5 | 1 |
GO:0032838 | plasma membrane bounded cell projection cytoplasm | 4 | 1 |
GO:0043233 | organelle lumen | 3 | 1 |
GO:0070013 | intracellular organelle lumen | 4 | 1 |
GO:0097014 | ciliary plasm | 5 | 1 |
GO:0099568 | cytoplasmic region | 3 | 1 |
GO:0110165 | cellular anatomical entity | 1 | 1 |
Related structures:
AlphaFold database: A4I1M2
Term | Name | Level | Count |
---|---|---|---|
GO:0006139 | nucleobase-containing compound metabolic process | 3 | 1 |
GO:0006725 | cellular aromatic compound metabolic process | 3 | 1 |
GO:0006807 | nitrogen compound metabolic process | 2 | 1 |
GO:0008152 | metabolic process | 1 | 1 |
GO:0009451 | RNA modification | 5 | 1 |
GO:0009892 | negative regulation of metabolic process | 4 | 1 |
GO:0009893 | positive regulation of metabolic process | 4 | 1 |
GO:0009894 | regulation of catabolic process | 4 | 1 |
GO:0009895 | negative regulation of catabolic process | 5 | 1 |
GO:0009987 | cellular process | 1 | 1 |
GO:0010468 | regulation of gene expression | 5 | 1 |
GO:0010604 | positive regulation of macromolecule metabolic process | 5 | 1 |
GO:0010605 | negative regulation of macromolecule metabolic process | 5 | 1 |
GO:0010608 | post-transcriptional regulation of gene expression | 6 | 1 |
GO:0010628 | positive regulation of gene expression | 6 | 1 |
GO:0016070 | RNA metabolic process | 5 | 1 |
GO:0016553 | base conversion or substitution editing | 6 | 1 |
GO:0016554 | cytidine to uridine editing | 7 | 1 |
GO:0019219 | regulation of nucleobase-containing compound metabolic process | 5 | 1 |
GO:0019222 | regulation of metabolic process | 3 | 1 |
GO:0031323 | regulation of cellular metabolic process | 4 | 1 |
GO:0031324 | negative regulation of cellular metabolic process | 5 | 1 |
GO:0031329 | regulation of cellular catabolic process | 5 | 1 |
GO:0031330 | negative regulation of cellular catabolic process | 6 | 1 |
GO:0034641 | cellular nitrogen compound metabolic process | 3 | 1 |
GO:0043170 | macromolecule metabolic process | 3 | 1 |
GO:0043412 | macromolecule modification | 4 | 1 |
GO:0043487 | regulation of RNA stability | 3 | 1 |
GO:0043488 | regulation of mRNA stability | 4 | 1 |
GO:0043489 | RNA stabilization | 4 | 1 |
GO:0044237 | cellular metabolic process | 2 | 1 |
GO:0044238 | primary metabolic process | 2 | 1 |
GO:0045934 | negative regulation of nucleobase-containing compound metabolic process | 6 | 1 |
GO:0046483 | heterocycle metabolic process | 3 | 1 |
GO:0048255 | mRNA stabilization | 5 | 1 |
GO:0048518 | positive regulation of biological process | 3 | 1 |
GO:0048519 | negative regulation of biological process | 3 | 1 |
GO:0048523 | negative regulation of cellular process | 4 | 1 |
GO:0050789 | regulation of biological process | 2 | 1 |
GO:0050794 | regulation of cellular process | 3 | 1 |
GO:0051171 | regulation of nitrogen compound metabolic process | 4 | 1 |
GO:0051172 | negative regulation of nitrogen compound metabolic process | 5 | 1 |
GO:0051252 | regulation of RNA metabolic process | 5 | 1 |
GO:0051253 | negative regulation of RNA metabolic process | 6 | 1 |
GO:0060255 | regulation of macromolecule metabolic process | 4 | 1 |
GO:0061013 | regulation of mRNA catabolic process | 6 | 1 |
GO:0065007 | biological regulation | 1 | 1 |
GO:0065008 | regulation of biological quality | 2 | 1 |
GO:0071704 | organic substance metabolic process | 2 | 1 |
GO:0080090 | regulation of primary metabolic process | 4 | 1 |
GO:0090304 | nucleic acid metabolic process | 4 | 1 |
GO:1901360 | organic cyclic compound metabolic process | 3 | 1 |
GO:1902369 | negative regulation of RNA catabolic process | 7 | 1 |
GO:1902373 | negative regulation of mRNA catabolic process | 7 | 1 |
GO:1903311 | regulation of mRNA metabolic process | 6 | 1 |
GO:1903312 | negative regulation of mRNA metabolic process | 7 | 1 |
Term | Name | Level | Count |
---|---|---|---|
GO:0003676 | nucleic acid binding | 3 | 1 |
GO:0003723 | RNA binding | 4 | 1 |
GO:0005488 | binding | 1 | 1 |
GO:0097159 | organic cyclic compound binding | 2 | 1 |
GO:1901363 | heterocyclic compound binding | 2 | 1 |
Leishmania | From | To | Domain/Motif | Score |
---|---|---|---|---|
CLV_C14_Caspase3-7 | 92 | 96 | PF00656 | 0.712 |
CLV_NRD_NRD_1 | 156 | 158 | PF00675 | 0.535 |
CLV_NRD_NRD_1 | 190 | 192 | PF00675 | 0.695 |
CLV_NRD_NRD_1 | 195 | 197 | PF00675 | 0.632 |
CLV_NRD_NRD_1 | 210 | 212 | PF00675 | 0.518 |
CLV_NRD_NRD_1 | 230 | 232 | PF00675 | 0.737 |
CLV_NRD_NRD_1 | 264 | 266 | PF00675 | 0.677 |
CLV_NRD_NRD_1 | 274 | 276 | PF00675 | 0.676 |
CLV_NRD_NRD_1 | 292 | 294 | PF00675 | 0.746 |
CLV_PCSK_KEX2_1 | 195 | 197 | PF00082 | 0.709 |
CLV_PCSK_KEX2_1 | 210 | 212 | PF00082 | 0.503 |
CLV_PCSK_KEX2_1 | 230 | 232 | PF00082 | 0.737 |
CLV_PCSK_KEX2_1 | 264 | 266 | PF00082 | 0.675 |
CLV_PCSK_KEX2_1 | 274 | 276 | PF00082 | 0.681 |
CLV_PCSK_KEX2_1 | 292 | 294 | PF00082 | 0.746 |
CLV_PCSK_PC7_1 | 191 | 197 | PF00082 | 0.696 |
CLV_PCSK_SKI1_1 | 103 | 107 | PF00082 | 0.651 |
CLV_PCSK_SKI1_1 | 129 | 133 | PF00082 | 0.528 |
CLV_PCSK_SKI1_1 | 151 | 155 | PF00082 | 0.549 |
CLV_PCSK_SKI1_1 | 158 | 162 | PF00082 | 0.508 |
DEG_Nend_UBRbox_1 | 1 | 4 | PF02207 | 0.629 |
DOC_MAPK_gen_1 | 191 | 200 | PF00069 | 0.606 |
DOC_PP4_FxxP_1 | 75 | 78 | PF00568 | 0.677 |
DOC_USP7_MATH_1 | 236 | 240 | PF00917 | 0.777 |
DOC_USP7_MATH_1 | 296 | 300 | PF00917 | 0.727 |
DOC_WW_Pin1_4 | 232 | 237 | PF00397 | 0.778 |
DOC_WW_Pin1_4 | 241 | 246 | PF00397 | 0.679 |
DOC_WW_Pin1_4 | 74 | 79 | PF00397 | 0.699 |
LIG_14-3-3_CanoR_1 | 191 | 195 | PF00244 | 0.684 |
LIG_14-3-3_CanoR_1 | 230 | 236 | PF00244 | 0.623 |
LIG_14-3-3_CanoR_1 | 300 | 305 | PF00244 | 0.709 |
LIG_14-3-3_CanoR_1 | 42 | 49 | PF00244 | 0.736 |
LIG_14-3-3_CanoR_1 | 9 | 17 | PF00244 | 0.713 |
LIG_FHA_1 | 112 | 118 | PF00498 | 0.609 |
LIG_FHA_2 | 163 | 169 | PF00498 | 0.540 |
LIG_FHA_2 | 59 | 65 | PF00498 | 0.611 |
LIG_LIR_Apic_2 | 72 | 78 | PF02991 | 0.687 |
LIG_LIR_Gen_1 | 130 | 139 | PF02991 | 0.521 |
LIG_LIR_Nem_3 | 130 | 135 | PF02991 | 0.479 |
LIG_SH2_SRC | 173 | 176 | PF00017 | 0.611 |
LIG_SH2_STAP1 | 36 | 40 | PF00017 | 0.697 |
LIG_SH2_STAT5 | 173 | 176 | PF00017 | 0.451 |
LIG_SH3_2 | 238 | 243 | PF14604 | 0.742 |
LIG_SH3_3 | 235 | 241 | PF00018 | 0.820 |
LIG_TRAF2_2 | 268 | 273 | PF00917 | 0.717 |
LIG_WRC_WIRS_1 | 150 | 155 | PF05994 | 0.513 |
MOD_CDK_SPK_2 | 74 | 79 | PF00069 | 0.637 |
MOD_CK1_1 | 127 | 133 | PF00069 | 0.482 |
MOD_CK1_1 | 234 | 240 | PF00069 | 0.803 |
MOD_CK1_1 | 5 | 11 | PF00069 | 0.769 |
MOD_CK1_1 | 50 | 56 | PF00069 | 0.793 |
MOD_CK1_1 | 59 | 65 | PF00069 | 0.803 |
MOD_CK1_1 | 69 | 75 | PF00069 | 0.690 |
MOD_CK1_1 | 99 | 105 | PF00069 | 0.527 |
MOD_CK2_1 | 149 | 155 | PF00069 | 0.514 |
MOD_CK2_1 | 162 | 168 | PF00069 | 0.393 |
MOD_CK2_1 | 58 | 64 | PF00069 | 0.612 |
MOD_Cter_Amidation | 262 | 265 | PF01082 | 0.841 |
MOD_GlcNHglycan | 13 | 16 | PF01048 | 0.759 |
MOD_GlcNHglycan | 132 | 135 | PF01048 | 0.518 |
MOD_GlcNHglycan | 238 | 241 | PF01048 | 0.842 |
MOD_GlcNHglycan | 30 | 33 | PF01048 | 0.525 |
MOD_GlcNHglycan | 36 | 39 | PF01048 | 0.637 |
MOD_GlcNHglycan | 52 | 55 | PF01048 | 0.808 |
MOD_GlcNHglycan | 58 | 61 | PF01048 | 0.789 |
MOD_GlcNHglycan | 97 | 101 | PF01048 | 0.620 |
MOD_GSK3_1 | 107 | 114 | PF00069 | 0.524 |
MOD_GSK3_1 | 232 | 239 | PF00069 | 0.723 |
MOD_GSK3_1 | 276 | 283 | PF00069 | 0.665 |
MOD_GSK3_1 | 296 | 303 | PF00069 | 0.709 |
MOD_GSK3_1 | 30 | 37 | PF00069 | 0.646 |
MOD_GSK3_1 | 43 | 50 | PF00069 | 0.610 |
MOD_GSK3_1 | 56 | 63 | PF00069 | 0.619 |
MOD_GSK3_1 | 74 | 81 | PF00069 | 0.647 |
MOD_N-GLC_1 | 280 | 285 | PF02516 | 0.749 |
MOD_N-GLC_1 | 300 | 305 | PF02516 | 0.815 |
MOD_N-GLC_1 | 90 | 95 | PF02516 | 0.609 |
MOD_NEK2_1 | 66 | 71 | PF00069 | 0.730 |
MOD_NEK2_2 | 124 | 129 | PF00069 | 0.465 |
MOD_PK_1 | 107 | 113 | PF00069 | 0.524 |
MOD_PK_1 | 2 | 8 | PF00069 | 0.689 |
MOD_PKA_2 | 190 | 196 | PF00069 | 0.692 |
MOD_PKA_2 | 50 | 56 | PF00069 | 0.813 |
MOD_PKA_2 | 69 | 75 | PF00069 | 0.649 |
MOD_Plk_1 | 107 | 113 | PF00069 | 0.572 |
MOD_Plk_1 | 300 | 306 | PF00069 | 0.767 |
MOD_Plk_4 | 107 | 113 | PF00069 | 0.524 |
MOD_Plk_4 | 127 | 133 | PF00069 | 0.290 |
MOD_ProDKin_1 | 232 | 238 | PF00069 | 0.779 |
MOD_ProDKin_1 | 241 | 247 | PF00069 | 0.677 |
MOD_ProDKin_1 | 74 | 80 | PF00069 | 0.696 |
TRG_ER_diArg_1 | 194 | 196 | PF00400 | 0.701 |
TRG_ER_diArg_1 | 229 | 231 | PF00400 | 0.701 |
TRG_ER_diArg_1 | 291 | 293 | PF00400 | 0.838 |
Protein | Taxonomy | Sequence identity | Coverage |
---|---|---|---|
A0A0N1I1H0 | Leptomonas seymouri | 43% | 96% |
A0A3S7WZ80 | Leishmania donovani | 99% | 100% |
A4HEG8 | Leishmania braziliensis | 70% | 99% |
E9AXQ6 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 91% | 100% |
Q4Q9R5 | Leishmania major | 91% | 100% |